ITA

Digital vs. Analog Mammography

Just as consumers today have to decide between analog and digital television sets, so, too, do physicians and radiology centers have to choose between analog and digital mammography units, with the latter rapidly gaining ground in imaging centers around the country. As of late 2003, the U.S. Food and Drug Administration (FDA) had cleared four digital mammography units for clinical use...

Samaritan's Alzheimer's Drug Caprospinol Suggests Brain May be Able to Heal From Alzheimer's Disease

Animal Study Confirms Caprospinol's (SP-233) Ability to Clear BrainPlaque and Empower Rat Brain Cells to Recover Memory Function In Vivo 'Proof of Concept' Study Proposes Direct CorrelationBetween Removing Beta Amyloid Plaque and Memory Recovery LAS VEGAS, July 10, 2007 (PRIME NEWSWIRE) -- SamaritanPharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs,is ple...

International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis

- ENDORSE Global Findings Highlight the Need to UrgentlyImplement Hospital-Wide Strategies to Optimize VTE Management:Systematically Assess Patient Risk for VTE and Provide Appropriateprophylaxis to Prevent VTE Venous thromboembolism (VTE) risk is high among hospitalpatients and most of these at-risk patients are not pro...

Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine

- Phase II Results Published in the Journal of Clinical Oncology - NEW YORK, July 06, 2007 /PRNewswire-FirstCall/ -- Results from aPhase II study - which will be published in the August 10, 2007issue of the Journal of Clinical Oncology (JCO) and are nowavailable as an Early Release Article at <a target="_blank" href="http://www.jco.org/">www.jco.org - demonstrate thatixabepilone, a Br...

Avexa's Apricitabine Clinical Trial Update

MELBOURNE, Australia--(BUSINESS WIRE)--Jul 5, 2007 - Australianbiotechnology company Avexa (ASX:AVX) announced today thecompletion of apricitabine's controlled, double blinded phase whichrepresents the first 24 week segment of its Phase IIb trial.Patients have now progressed into the open-label section of thetrial (weeks 24 to 48) and will continue to receive 800mgapricitabine twice a day a...

Common Preterm Labor Drug Has More Side Effects Than Alternative, Finds Study from Packard Children's Hospital and Stanford

STANFORD, Calif.--(BUSINESS WIRE)--Jun 29, 2007 - The drug mostcommonly used to arrest preterm labor, magnesium sulfate, is morelikely than another common treatment to cause mild to serious sideeffects in pregnant women, according to a study from researchers atLucile Packard Children's Hospital and Stanford University Schoolof Medicine. Their findings suggest that, since the effectivenessof...

An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes

CHICAGO--(BUSINESS WIRE)--Jun 25, 2007 - New data from aninvestigational study released at the American Diabetes Association(ADA) 67th Annual Scientific Sessions showed that initialcombination therapy with Januvia(TM) (sitagliptin) and metformindemonstrated significant improvement in markers of beta cellfunction in patients with type 2 diabetes. Pancreatic islet betacell function determines...

Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial

~ Valopicitabine achieved both primary and secondary endpoints ofstudy; no negative drug-drug interaction was observed betweenvalopicitabine and ribavirin ~ CAMBRIDGE, Mass., June 12, 2007 /PRNewswire-FirstCall/ -- IdenixPharmaceuticals, Inc. today announced results from a phase II studydesigned to evaluate triple combination therapy, consisting ofvalopicitabine (NM283), Idenix's lead dru...

Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)

Results show risk of heart attackcomparable to two widely used diabetes medicines - A studyof more than 33,000 type 2 diabetes patients in a real-worldsetting was published today. This study shows that the incidence ofhospitaliations f...

Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death

"Patients and physicians should find these data reassuring" PHILADELPHIA, June 05, 2007 /PRNewswire-FirstCall/ --GlaxoSmithKline said today that findings from an interim analysisof RECORD (Rosiglitazone Evaluated for Cardiac Outcomes andRegulation of glycemia in Diabetes), a prospective clinical trialdesigned specifically to determine cardiovascular outcomes in morethan 4,400 patients wit...

New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel

22 US Oncology Affiliated Physicians Participate in ASCOProceedings HOUSTON, June 04, 2007 /PRNewswire/ -- A leading cancerresearcher affiliated with the US Oncology Research Networkpresented findings from a randomized, multicenter phase III trialthat compared the disease-free survival (DFS) obtained with tworegimens of adjuvant therapy for patients with high-risk breastcancer. Th...

XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer

ASCO publication highlights health care cost benefit ofbioengineering paclitaxel CHICAGO, June 05, 2007 /PRNewswire-FirstCall/ -- CellTherapeutics, Inc. (CTI) announced that data published in the 2007Annual Meeting of the American Society of Clinical Oncology (ASCO)abstracts showed reduced medical resource utilization (MRU) andassociated costs with XYOTAX (paclitaxel polyglumex) treatment...

Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema

NEW YORK, May 31, 2007 /PRNewswire-FirstCall/ -- LevPharmaceuticals, Inc. ("Lev" or the "Company") announced today thatit has completed patient treatment in the prophylactic portion ofits Phase III clinical trial of C1-esterase inhibitor (C1-INH) forhereditary angioedema (HAE). The clinical trial, designated CHANGE,examined and evaluated the efficacy and safety of C1-INHreplacement thera...

Mild Asthma, a Revolutionary Therapy from Italian Research

Published by the New England Journal of Medicine the B.E.S.Tstudy conducted in Italy “TAKEN ONLY WHEN NEEDED AND THE DISEASE CAN BE CONTROLLEDSUCCESSFULLY” Prof. Fabbri: “Daily drug useless for mild persistenttypes affecting over one million 200 thousand people”.Chiesi’s commitment to pneumological research MILAN, Italy, 29th May 2007 &nda...

Cyclacel Pharmaceuticals to Report Sapacitabine Phase I Study Results at the American Society of Clinical Oncology Annual Meeting

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--May 24, 2007 - CyclacelPharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) announced todaythat it will report results from a Phase I pharmacologic trial ofsapacitabine (CYC682), a novel orally-available nucleoside analog,in patients with advanced leukemias or myelodysplastic syndromes(MDS), at the American Society of Clinical Oncology's (ASCO) Annual...

Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax

Single-Dose Protection Observed Prior to or Up to 24 Hours AfterExposure to Anthrax TORONTO, Ontario, May 24, 2007 /PRNewswire/ -- TargantaTherapeutics Corporation announced today the results from a recentstudy demonstrating oritavancin as a potential therapy for treatingexposure to Bacillus anthracis, the bacterium which causes anthrax,an acute infectious disease. Oritavancin, a novel se...

Phase 2a Diarrhea Predominant Irritable Bowel Syndrome Results from 2006 Presented at Digestive Disease Week in Washington, D.C.

SOUTH SAN FRANCISCO, Calif., May 23, 2007 /PRNewswire-FirstCall/-- Napo Pharmaceuticals, Inc., , which focuses on the developmentand commercialization of proprietary pharmaceuticals for the globalmarketplace in collaboration with local partners, announced thatTrine Pharmaceuticals, Inc. ("Trine") is presenting a posterdetailing the results of a Phase 2a study conducted in 2006 forcrofele...

Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years

Trial results report no new stent thrombosis after two years inhigh-risk patient population NATICK, Mass., and BARCELONA, Spain, May 22, 2007/PRNewswire-FirstCall/ -- Boston Scientific Corporation todayannounced four-year follow-up data from its TAXUS VI clinicaltrial. The data demonstrated that the safety and efficacy benefitsassociated with a moderate-release formulation of the TAXUS(R)...

New Analysis of Data Shows Treatment With Abbott's Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohn's Disease

HUMIRA Data Showed 57 Percent Reduction in Risk of Hospitalizationfrom Crohn's Disease vs. Placebo at One Year ABBOTT PARK, Ill., May 22, 2007 /PRNewswire-FirstCall/ -- Abbotttoday announced results from a post-hoc analysis of a pivotal studypresented at the Digestive Disease Week annual meeting inWashington, D.C. showing patients with moderate to severely activeCrohn's disease treated wi...

Alterations in Intestinal Serotonin in Irritable Bowel Syndrome and Dyspepsia

ROCHESTER, MN, May 21, 2007-- Serotonin is aneurotransmitter that helps regulate intestinal functions. MayoClinic researchers set out to determine the role of serotonin inpatients with IBS and dyspepsia. The study involved 48 females --including individuals with IBS, individuals with dyspepsia,individuals with both IBS and dyspepsia, and healthy volunteers.Biopsies were obtained from the...

Nektar Threraputics Announces Phase 2a Clinical Results Regarding the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative Hospital-Acquired Pneumonia Presented at the Annual American Thoracic Society International Conference

SAN FRANCISCO--(BUSINESS WIRE)--May 21, 2007 - Medicalprofessionals seeking to treat the serious and growing problem ofhospital-acquired gram-negative pneumonia may have a new weapon:NKTR-061 (inhaled-amikacin), which is a product candidate beingdeveloped by Nektar Therapeutics (Nasdaq:NKTR). Results of a Phase 2a clinical trial evaluating the use ofNKTR-061 (Inhaled Amikacin) to treat me...

New Study Demonstrates that Lubiprostone May Improve Symptom Relief Rates in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

WASHINGTON, May 21, 2007 /PRNewswire/ -- A new studydemonstrated that the active ingredient in Amitiza (lubiprostone),given 8 mcg twice a day, may improve symptom relief rates in adultswith irritable bowel syndrome with constipation (IBS-C). Theseresults were presented as a late-breaker at Digestive Disease Week2007, the largest annual international meeting of digestive diseasespecialist...

New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace

First comprehensive study of market dynamics offers insights intowhat will be needed to get new, faster and better TB drugs topatients NEW YORK, May 14, 2007 /PRNewswire-USNewsire/ -- The GlobalAlliance for TB Drug Development (TB Alliance), a not-for-profit,product development partnership accelerating the discovery anddevelopment of new TB drugs, today released results from the firstcom...

Samaritan Announces Positive Data in Nonclinical (IND) In-Vitro Studies for Promising Alzheimer's Drug

Samaritan Announces Positive Data in Nonclinical (IND) In- VitroStudies for Promising Alzheimer's Drug LAS VEGAS, May 3, 2007 (PRIME NEWSWIRE) -- SamaritanPharmaceuticals Inc. (AMEX:LIV), a developer of innovative drugs,is pleased to announce positive results were attained with itslate-stage preclinical/nonclinical testing of Caprospinol (SP-233),with well recognized in-vitro models....

Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh to be Presented at European Vascular Symposium

STRASBOURG, France and VANCOUVER, April 26, 2007/PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. , a globalspecialty pharmaceutical and medical device company, announced thatthe two-year data from its European pivotal trial examining theVascular Wrap(TM) Paclitaxel-Eluting Mesh ("Vascular Wrap(TM)")will be presented today at a scientific forum in Europe. Thetwo-year study examine...

Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response

LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScience,Inc. (NASDAQ:ABBI), an integrated, global biopharmaceuticalcompany, discussed results from two pre-clinical studies thatprovide evidence for chemotherapy induced angiogenesis andrationale for combining nab-paclitaxel (ABRAXANE(R) for InjectableSuspension (paclitaxel protein-bound particles for injectablesuspension) (albumin-bou...

Oncolytics Biotech Inc. Research Collaborators Demonstrate Reovirus/Gemcitabine Combination Has Synergistic Effect Against Human Colon Cancer Cell Lines

CALGARY, April 17, 2007 /PRNewswire-FirstCall/ - OncolyticsBiotech Inc. ("Oncolytics") announces that a poster by Dr. MaureenE. Lane et al. of , New York, entitled "In Vivo Synergy betweenOncolytic Reovirus and Gemcitabine in Ras-Mutated Human HCT116Xenografts" is scheduled to be presented today at the AmericanAssociation for Cancer Research (AACR) Annual Meeting in LosAngeles, CA. The m...

DX-88 for Hereditary Angioedema Meets Primary and Secondary Endpoints in Phase 3 Trial (EDEMA3)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2007 - Dyax Corp.(Nasdaq:DYAX) announced today positive topline results from itsPhase 3, placebo-controlled trial, EDEMA3, for its lead productcandidate DX-88 (ecallantide), for hereditary angioedema (HAE). Awebcast presentation of the EDEMA3 data is scheduled for Tuesday,April 17, 2007 at 12:30 p.m. ET. DX-88, an internally discovered, recombina...

Idenix Reports Results from Two Phase IIb Studies of the Combination of Valopicitabine and Pegylated Interferon in Hepatitis C Genotype-1 Patients at the 42nd Annual Meeting of the European Association for the Study of the Liver

Additional Preclinical Data Presented on Valopicitabine Combinedwith an Investigational Protease Inhibitor BARCELONA, Spain, April 12, 2007 /PRNewswire-FirstCall/ --Idenix Pharmaceuticals, Inc. today announced results from two phaseIIb studies of the novel combination of valopicitabine (NM283) andpegylated interferon alfa-2a (Pegasys(R)) in both treatment-naiveand treatment- experienced p...

Cyclacel Pharmaceuticals to Present Preclinical Data on Sapacitabine and Seliciclib at AACR

BERKELEY HEIGHTS, N.J.--(BUSINESS WIRE)--Apr 11, 2007 - CyclacelPharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) announcedtoday that scientists from the company will present results of twopreclinical studies with sapacitabine and seliciclib, the company'smost advanced drug candidates in clinical development. The resultswill be reported in two poster presentations during the upcomingAnnu...

Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics

Three Oritavancin Studies Presented at ECCMID/ICC MUNICH, Germany, April 03, 2007 /PRNewswire/ -- TargantaTherapeutics today announced results from two studies showing theimproved potency of oritavancin to stop bacterial growth in vitrowhen tested with a common wetting agent (polysorbate 80) and onestudy demonstrating the activity of oritavancin against S.pneumoniae in a mouse model of pn...

Six Important Things to Know About Preventing Hospital Infections

Infection Control Professional Offers Patient Tips to Guard AgainstHospital Infections KANSAS CITY, Kan., April 02, 2007 /PRNewswire/ -- Hospitalinfections are among the top ten leading causes of death in theUnited States, according to the Centers for Disease Control. Thereare countless stories about patients who go into hospitals withminor conditions and leave under much graver circumsta...

Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show

NEW ORLEANS--(BUSINESS WIRE)--Mar 27, 2007 - Pfizer announced todaythat Lipitor(R) (atorvastatin calcium) Tablets (80 mg) loweredhospitalization costs by significantly reducing the risk ofcardiovascular events in patients with heart disease, according totwo separate economic analyses. The data were presented at theannual meeting of the American College of Cardiology. "One of these analyse...

Alexza's AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation

Initial Analysis Shows Statistically Significant Changes inAgitation Levels With 10 mg AZ-004 PALO ALTO, Calif., March 26, 2007 /PRNewswire-FirstCall/ --Alexza Pharmaceuticals, Inc. today announced positive initialresults from its Phase IIa clinical trial of AZ-004 (Staccato(R)loxapine) in schizophrenic patients with acute agitation. The 10 mgdose of AZ-004 met the primary endpoint of the...

Hospitalization Rates for Coronary Artery Disease Decline in the U.S.

EVANSTON, Ill., March 20, 2007 /PRNewswire/ -- Treatment ofcoronary artery disease (CAD) appears to be shifting away from theinpatient setting, according to a study published today in TheAmerican Journal of Cardiology. U.S. hospitalization rates for heart attacks (acute myocardialinfarctions) declined 10.6 percent from 2002 to 2005, possibly dueto broader use of preventive treatmen...

Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III Trial for Hereditary Angioedema

Company anticipates second quarter BLA filing for C1-inhibitorreplacement therapy NEW YORK, March 14, 2007 /PRNewswire-FirstCall/ -- LevPharmaceuticals, Inc. (Lev) today announced positive results fromits pivotal U.S. Phase III trial of C1-esterase inhibitor (C1-INH)for the acute treatment of hereditary angioedema (HAE). In theacute study, which is part of the company's CHANGE trials(C1-...

Oncolytics Biotech Inc. Collaborators to Present Reovirus/Gemcitabine Combination Research at AACR Annual Meeting

CALGARY, March 13, 2007 /PRNewswire-FirstCall/ - OncolyticsBiotech Inc. announced today that an abstract covering preclinicalwork using reovirus in combination with gemcitabine is availabletoday on the American Association for Cancer Research (AACR)website at <a target="_blank" href="http://www.aacr.org/">www.aacr.org , and on the Oncolyticswebsite at <a target="_blank" href="http://...

Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy

- Helix BioPharma Corp. (TSX: HBP /Frankfurt: WKN918864) AURORA, ON, March 5 /CNW/Dr. Heman Chao, Vice President of Researchat Helix BioPharma Corp., a developer of novel cancer therapeutics,will be presenting a scientific poster at the Fourth InternationalConference on Tumor Microenvironment, which runs from March 6th to10th in Florence, Italy. The conf...